MB
This company develops gene-editing therapies to treat Duchenne muscular dystrophy by targeting the underlying genetic cause of the disease. Their technology aims to significantly impact disease progression for patients with this muscle disorder.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- This company develops gene-editing therapies to treat Duchenne muscular dystrophy by targeting the underlying genetic cause of the disease. Their technology aims to significantly impact disease progression for patients with this muscle disorder.